|
1
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697.
2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ATTRACTION-2): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet. 390:2461–2471.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with microsatellite instability-high (MSI-H) advanced solid tumors:
Results from the KEYNOTE-158 study. J Clin Oncol. 38:1–10.
2020.
|
|
6
|
Shitara K, Bang YJ, Iwasa S, Sugimoto N,
Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, et al:
Trastuzumab deruxtecan in previously treated HER2-positive gastric
cancer (DESTINY-Gastric01): A randomised, open-label, phase 2
trial. N Engl J Med. 382:2419–2430. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shitara K, Lordick F, Bang YJ, Enzinger P,
Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al:
Zolbetuximab plus mFOLFOX6 for first-line treatment of
CLDN18.2-positive, HER2-negative advanced gastric or
gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A
multicentre, randomised, double-blind, phase 3 trial. Lancet.
401:1655–1668. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shah MA, Shitara K, Ajani JA, Bang YJ,
Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J,
Huang J, et al: Zolbetuximab plus CAPOX in patients with
CLDN18.2-positive, HER2-negative advanced gastric or
gastro-oesophageal junction adenocarcinoma (GLOW): A randomised,
double-blind, phase 3 trial. Nat Med. 29:2133–2141. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Japanese Gastric Cancer Association.
Guidelines for Biomarker Testing, 2nd edition. Kanehara & Co.,
Ltd., Tokyo, 2025.
|
|
10
|
Van Cutsem E, Bang YJ, Feng F, Xu JM, Lee
KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, et al:
HER2 screening data from ToGA: Targeting HER2 in gastric and
gastroesophageal junction cancer. Gastric Cancer. 18:476–484.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Japanese Gastric Cancer Association.
Japanese Classification of Gastric Carcinoma, 15th edition.
Kanehara & Co., Ltd., Tokyo, 2017.
|
|
12
|
Japanese Society of Pathology. Japanese
Guidelines for HER2 Testing in Breast Cancer/Gastric Cancer. 2nd
edition. Kanehara & Co., Ltd Tokyo, 2021.
|
|
13
|
Abe H, Kuwata T, Kushima R and Ushiku T:
Nationwide survey on HER2 and PD-L1 testing practices in gastric
cancer across Japan. Gastric Cancer. 28:294–300. 2025.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Park SR, Park YS, Ryu MH, Ryoo BY, Woo CG,
Jung HY, Lee JH, Lee GH and Kang YK: Extra-gain of HER2-positive
cases through HER2 reassessment in primary and metastatic sites in
advanced gastric cancer with initially HER2-negative primary
tumours: Results of GASTric cancer HER2 reassessment study 1
(GASTHER1). Eur J Cancer. 53:42–50. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yoshida K, Yasufuku I, Terashima M, Young
Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S,
et al: International retrospective cohort study of conversion
therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Surg Oncol.
25:2530–2538. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Fujitani K, Kurokawa Y, Wada R, Takeno A,
Kawabata R, Omori T, Imamura H, Hirao M, Endo S, Kawada J, et al:
Prospective single-arm multicenter interventional study of surgical
resection for liver metastasis from gastric cancer: 3-year overall
and recurrence-free survival. Ann Surg Oncol. 27:3775–3783.
2020.
|
|
17
|
Hall PS, Swinson D, Cairns DA, Waters JS,
Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, et al:
Efficacy of reduced-intensity chemotherapy with oxaliplatin and
capecitabine on quality of life and cancer control among older and
frail patients with advanced gastroesophageal cancer: The GO2 phase
3 randomized clinical trial. JAMA Oncol. 7:869–877. 2021.PubMed/NCBI View Article : Google Scholar
|
